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AbstrACt
Objectives To investigate beliefs about medicines and 
their association with medicine adherence in patients with 
chronic diseases in China.
Design A cross-sectional questionnaire-based study
setting Two large urban hospitals in Hefei and Tianjin, 
China
Participants Hospital inpatients (313 stroke patients) and 
outpatients (315 diabetic patients and 339 rheumatoid 
arthritis (RA) patients) were recruited between January 
2014 and September 2014.
Outcome measures The Beliefs about Medicines 
Questionnaire (BMQ), assessing patients’ beliefs about 
the specific medicine (Specific-Necessity and Specific-
Concerns) prescribed for their conditions (stroke/
diabetes/RA) and more general background beliefs about 
pharmaceuticals as a class of treatment (BMQ-General 
Benefit, Harm and Overuse); the Perceived Sensitivity to 
Medicines scale (PSM) assessed patients’ beliefs about 
how sensitive they were to the effects of medicines and 
the Medication Adherence Report Scale. The association 
between non-adherence and beliefs about medicines was 
assessed using a logistic regression model.
results Patients with diabetes mellitus had a stronger 
perceived need for treatment (mean (SD) Specific-
Necessity score, 3.75 (0.40)) than patients with stroke 
(3.69 (0.53)) and RA (3.66 (0.44)) (p=0.049). Moderate 
correlations were observed between Specific-Concerns 
and General-Overuse, General-Harm and PSM (Pearson 
correlation coefficients, 0.39, 0.49 and 0.49, respectively, 
p<0.01). Three hundred and eleven patients were non-
adherent to their medicine (159 (51.0%) in the stroke 
group, 60 (26.7%) in the diabetes mellitus group and 
62 (19.8%) in the RA group, p<0.01). Across the whole 
sample, after adjusting for demographic characteristics, 
non-adherence was associated with patients who had 
higher concerns about their medicines (OR, 1.35, 95% CI 
1.07 to 1.71) and patients who believed that they were 
personally sensitive to the effects of medications (OR 1.44, 
95% CI 1.16 to 1.85).
Conclusion The BMQ is a useful tool to identify patients 
at risk of non-adherence. In the future, adherence 
intervention studies may use the BMQ to screen for 
patients who are at risk of non-adherence and to map 
interventional support.
IntrODuCtIOn
Medicine plays an essential role in chronic 
disease management. However, it is 
recognised that only half of patients with 
chronic diseases take their medicines as 
prescribed.1 Stroke, diabetes mellitus and 
rheumatoid arthritis (RA) are three common 
chronic diseases which together affect over 
10% of China’s population of 1.40 billion.2–5 
Stroke is the leading cause of adult death and 
disability in China with an annual mortality 
rate of approximately 1.6 million, or 157 per 
100 000.6 Patients with chronic diseases often 
require multiple medicine treatments for 
their conditions and any associated symptoms 
and comorbidities. To obtain full benefit 
from treatment, patients need to adhere to 
these complex medicine regimens in order 
to control their disease and maintain health. 
However, in reality, medicine management 
is suboptimal and relates to physician inertia 
and patients’ poor adherence with therapy.7 
The elderly, with high rates of comor-
bidity and coprescribing, tend to have poor 
strengths and limitations of this study
 ► First large study of beliefs about medicines in China.
 ► High response rate, reflecting generalisability of the 
study finding.
 ► A cross-sectional design implicating that the 
association between non-adherence and beliefs 
about medicines did not necessarily lead a causal 
relationship.
 ► Self-reported adherence may not be the best 
measurement for medicine adherence.
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adherence and are at particular risk of unwanted adverse 
effects from drugs.8 9
Studies outside China have identified patients’ beliefs 
about medicines as an important determinant of non-ad-
herence.10 A recent meta-analysis of 96 peer-reviewed 
studies involving over 24 000 patients across 24 long-
term conditions and 18 countries showed that non-ad-
herence was related to patients beliefs about medicines, 
measured by the Beliefs about Medicines Questionnaire 
(BMQ).10 These studies indicated that there was often 
a disconnect between the patients and prescribers view 
of the medicine. Many patients doubted their personal 
need for the treatment or harboured concerns and these 
beliefs are associated with non-adherence. Beliefs about 
medicines may also be relevant in China, particularly as 
there is some evidence that trust between patients and 
health professionals may have diminished after China’s 
economic reform.11 12 Patients often do not trust their 
doctors and doubt the treatment including therapeutic 
treatment they received. It is possible that this may trans-
late into scepticism about prescribed medicines and 
non-adherence. The aim of this study was to understand 
beliefs about medicines in Chinese patients with stroke, 
diabetes mellitus and RA and to investigate whether these 
beliefs are associated with medicine non-adherence.
MethODs
A cross-sectional study was conducted in two large 
teaching hospitals in China between January 2014 and 
November 2014. The study was approved by the local 
research ethics committees.
study populations and recruitment
Patients with stroke were recruited from The Second 
Hospital, Tianjin Medical University, Tianjin, China and 
patients with diabetes mellitus and RA were recruited 
from Anhui Provincial Hospital, Anhui Medical Univer-
sity, Hefei, China. Both hospitals are large teaching 
hospitals and are level 3 general hospitals, the highest 
classification for quality care given by China’s National 
Health and Family Planning Commission for all public 
hospitals.13 Patients who had a clinical diagnosis of stroke, 
diabetes mellitus or RA who were judged by the healthcare 
professionals as able to answer questions were invited by 
the healthcare professionals to take part in the study when 
they were admitted to the hospital (stroke patients) or 
came to hospital clinics (diabetic and RA patients) during 
the study period. Some patients may have comorbidity. 
However, they were only included for the condition they 
were hospitalised or the condition from the specific outpa-
tient clinics. They were asked to complete a questionnaire 
which took approximately 10–15 min. Study information 
was given to patients and verbal consent was obtained 
before they started to fill in the questionnaire. All invited 
patients returned their questionnaires. Since there is a 
lack of research on beliefs about medicines and medi-
cine non-adherence in China, a target sample size of 300 
patients for each condition was chosen based on typical 
sample sizes used in similar surveys. A recent meta-anal-
ysis showed that small–moderate effect of psychological 
beliefs on medicine adherence was observed in 94 studies 
with an average sample size of 266.10 Data collection 
started in January 2014 and lasted around 4 months for 
each condition and was stopped once the target numbers 
were reached (November 2014).
Questionnaire measurement
The questionnaire consisted of demographic informa-
tion, the BMQ questionnaire,14 perceived sensitivity to 
medicines scale (PSM) and medicine adherence report 
scale (MARS).15 All scales were translated and back trans-
lated in accordance with the Originator’s conditions 
to create a Chinese version, (BMQ-Chinese © R Horne 
MARS-Chinese © R Horne, PSM-Chinese © R Horne). 
The BMQ and MARS were translated into Chinese by 
LW, the principal investigator for this study. They were 
then sent to the coauthors, XL and XL for comments and 
further adaptation resulting in a final Chinese version of 
the BMQ.
Demographic information included name, age, gender, 
education, occupation and duration of the condition. 
The BMQ questionnaire has two parts: the BMQ-Spe-
cific assessing beliefs about medicine used for a partic-
ular condition and the BMQ-General assessing beliefs 
about medicines in general. The details of the BMQ 
questionnaire can be found in a previous publication.8 
In brief, BMQ-Specific comprised two scales: a five-item 
treatment necessity scale Specific-Necessity and a six-item 
treatment concern scale Specific-Concern. BMQ-Gen-
eral used three subscales: (1) General-Overuse (four 
items), (2) General-Harm (four items) and (3) Gener-
al-Benefit (four items). Perceived Sensitivity to Medicines 
(PSM) scale contained five items assessing perceptions 
of personal susceptibility to the effects of medicines. All 
BMQ items and PSM were scored on a Likert type scale 
(where 1=strongly disagree, 2=disagree, 3=uncertain, 
4=agree and 5=strongly agree). A mean item score was 
then calculated as the sum of each item score divided by 
the number of items (eg, mean score of Specific-Neces-
sity= (N1 +N2+N3+N4+N5)/5). The Cronbach’s αs indi-
cated that all scale measures were internally consistent 
in the study sample16 with high value of αpsm=0.85, αcon-
cern=0.75 and αnecessity=0.64, and low values of αoveruse= 0.54, 
αharm=0.55 and αbenefit=0.58. For BMQ-Specific, patients 
were only asked for the treatment prescribed for the diag-
nosed condition in the past 12 months. Medicine adher-
ence was measured for the same period using the MARS 
scale consisting of five items with 25 score points in total. 
For example, one item is ‘I forget to take them’.
Before the study commenced, 30 people including 
doctors, nurses, medical students and patients were 
asked to complete the questionnaire to assess whether 
the Chinese version of the BMQ, PSM and MARS would 
be easily understood by Chinese patients. Feedback was 
wholly positive; however, we recognised that patients were 
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likely to be elderly and may have poor literacy. Therefore, 
arrangements were made to provide help should patients 
have any difficulty completing the questionnaire. Patients 
in both centres completed the questionnaire either by 
themselves or with help from the healthcare professionals 
in the medical ward or clinic they attended. Healthcare 
professionals received a briefing from the local investi-
gators on how to complete the questionnaire including 
instructions on how to explain the meaning of the ques-
tionnaire items without influencing patients’ responses.
Definition of adherence and non-adherence
It is commonly accepted that it is not necessary to take 
100% of a prescribed treatment, and 80% adherence is 
a commonly used cut-off to define adherence, especially 
in medicine benefit/safety studies.17 While the MARS 
scale does not allow direct assessment of the percentage 
of prescribed treatment taken, we used a cut-off of 20 out 
of 25 on this scale to define adherence, indicating that 
patients are taking a large proportion of their prescribed 
doses. Adherence was calculated as sum of the scores from 
each item divided by the maximum points of 25 using 
the five-item MARS scale. Non-adherent patients were 
defined as having a score <80% adherence to medicine.
Attitudinal analysis
Participants were categorised into attitudinal groups (ie, 
Sceptical, Ambivalent, Indifferent and Accepting groups) 
based on whether they scored above or below the scale 
midpoint for BMQ necessity and concerns scales. Non-ad-
herence was investigated between the groups.17
statistical analysis
Data were presented as mean (SD) for continuous vari-
ables and as frequencies (%) for categorical variables. χ2 
and analysis of variance tests were performed to deter-
mine significant differences between the three diseases. 
Correlations were used to examine relationships between 
BMQ-General and BMQ-Specific subscales. Logistic 
regression analysis was employed to assess the associa-
tion between non-adherence and medicine beliefs. Five 
per cent of patients had at least one missing value in their 
BMQ answers and the total missing values were 0.3% 
for the whole BMQ items. A sensitivity analysis was done 
to include all patients with missing data replaced with 
imputed data in the multivariable analysis concluding all 
variables listed in table 1. The multiple imputation anal-
ysis included all variables used in the final analysis with 
10 imputations by using the Markov Chain Monte Carlo 
method to produce imputed data. All statistical analyses 
were carried out using SAS (V.9.4).
results
Patient characteristics
There were 967 patients in the study (313 with stroke, 315 
with diabetes mellitus and 339 with RA). Table 1 shows 
the demographic and clinical information by disease 
groups. Patients with RA were significantly younger than 
patients with stroke and diabetes mellitus (mean age 49.7 
vs 65.8 and 62.5, respectively). The RA group was 85% 
female while only 44% of stroke patients and 45% of 
diabetes mellitus patients were female. Patients with RA 
were five times more likely to report having received no 
formal education than patients with stroke and diabetes 
mellitus (23.3% vs 4.8% and 4.1%, respectively). Over 
half of patients in the stroke group had less than 1 year 
disease duration while more than half of the patients in 
the RA and diabetes mellitus groups had more than 5 
years disease duration.
bMQ results
The results of BMQ subscales are shown in table 2. There 
were no significant differences in the mean scores of 
Specific-Concerns and General-Harm between the three 
groups. However, differences were observed for Specif-
ic-Necessity, General-Overuse, General-Benefit and PSM 
among the three groups. Patients with RA had the highest 
score of 3.75 (SD 0.40) for Specific-Necessity and lowest 
scores of 2.95 (SD 0.51) for General-Overuse and 3.55 (SD 
0.45) for General-Benefit. The mean scores of PSM were 
2.89 (SD 0.65), 2.35 (SD 0.64) and 2.70 (SD 0.68). The 
attitudinal analysis categorised patients into four groups 
(high/low necessity and high/low concerns) according 
to the midpoint of the Specific-Necessity Specific-Con-
cerns, scales shows that 45% of patients were classified as 
‘Ambivalent’, 45% as ‘Accepting’, 4% as ‘Sceptical’ and 
6% as ‘Indifferent’ (figure 1).
Patients’ general beliefs about medicines were asso-
ciated with their evaluations of the specific treatments 
they were taking. Table 3 shows the correlation between 
BMQ-General and BMQ-Specific. Specific-Necessity 
was positively associated with General-Benefit (Pearson 
correlation coefficients=0.31, p<0.01). Moderate correla-
tions were observed between Specific-Concerns and 
General-Overuse, General-Harm and PSM (Pearson 
correlation coefficients, 0.39, 0.49 and 0.49, respectively, 
p<0.01). General-Overuse was also correlated with Gener-
al-Harm and PSM (Pearson correlation coefficients, 0.45 
and 0.39, respectively, p<0.01). The Pearson correlation 
coefficient was 0.39 (p<0.01) for General-Harm and PSM.
Association between beliefs about medicines and non-
adherence
Three hundred and eleven patients were non-adherent 
to their medicine (159 (51.0%) in the stroke group, 60 
(26.7%) in the diabetes mellitus group and 62 (19.8%) 
in the RA group, p<0.01). After adjusting for demo-
graphic characteristics, Specific-Concerns and PSM were 
significantly associated with non-adherence (adjusted 
ORs, 1.35, 95% CI 1.07 to 1.71 and 1.44, 95% CI 1.16 
to 1.80). Negative associations between non-adherence 
and Specific-Necessity and General-Benefit were not 
statistically significant (table 4). The subgroup analyses 
showed that the point estimates of Specific-Concerns 
were positively associated with non-adherence across the 
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three conditions, that is, the more concerns about the 
medicines, the more non-adherent to medicines, with 
adjusted ORs ranging from 1.15 (95% CI 0.67 to 1.98) 
for diabetes mellitus to 1.43 (95% CI 1.02 to 2.00) for 
stroke (table 5). The unadjusted results showed similar 
results across the three disease conditions. The sensitivity 
analysis showed that Specific-Concerns and PSM were 
positively associated with non-adherence (adjusted ORs, 
1.15 95% CI 1.04 to 1.26 and 1.40, 95% CI 1.04 to 1.26, 
respectively) and General-Benefit was negatively associ-
ated with non-adherence (adjusted OR 0.79, 95% CI 0.71 
to 0.87). Compared with patients in the Accepting group, 
patients in the other attitudinal groups were more likely 
to be the non-adherent (adjusted ORs, 1.50 95% CI 1.10 
Table 1 Patient characteristics by conditions
Stroke n=313 (100%) Diabetes n=315 (100%) RA n=339 (100%)
Age, mean (SD)* 65.8 (13.7) 62.5 (13.9) 49.7 (12.8)
Gender†*
  Women 136 (43.5%) 141 (44.8%) 287 (85.2%)
  Men 177 (56.5%) 174 (55.2%) 50 (14.8%)
Education*
  Illiteracy (no formal education) 15 (4.8%) 13 (4.1%) 79 (23.3%)
  Primary school 66 (21.1%) 62 (19.7%) 93 (27.4%)
  Junior high school 60 (19.2%) 91 (28.9%) 91 (26.8%)
  High school/college 116 (37.1%) 77 (24.4%) 48 (14.2%)
  University or above 54 (17.2%) 70 (22.2%) 25 (7.4%)
  Unknown 2 (0.6%) 2 (0.6%) 3 (0.9%)
Occupation*
  Farmer 5 (1.6%) 22 (7.0%) 110 (32.5%)
  Worker/clerk 83 (26.5%) 117 (37.1%) 38 (11.2%)
  Housewife/unemployment 45 (14.4%) 12 (3.8%) 113 (33.3%)
  Retirement 129 (41.2%) 54 (17.1%) 40 (11.8%)
  Health professional 19 (6.1%) 29 (9.2%) 15 (4.4%)
  Civil service 29 (9.3%) 72 (22.9%) 11 (3.2%)
  Unknown 3 (1.0%) 9 (2.9%) 12 (3.5%)
Duration of the disease*
  <=1 year 178 (56.9%) 20 (6.4%) 55 (16.2%)
  1–5 years 91 (29.1%) 74 (23.5%) 104 (30.7%)
  >5 year 44 (14.1%) 220 (69.8%) 177 (52.2%)
   Unknown 0 (0.0%) 1 (0.3%) 3 (0.9%)
*<0.05.
†Excluding missing data.
RA, rheumatoid arthritis.
Table 2 Results of BMQ and PSM by disease conditions
Stroke n=313 Diabetes n=315 RA n=339
Specific-Necessity (mean, SD)*† 3.69 (0.53) 3.75 (0.40) 3.66 (0.44)
Specific-Concerns (mean, SD)† 3.03 (0.71) 3.15 (0.58) 3.07 (0.58)
General-Overuse (mean, SD)*† 3.22 (0.62) 3.12 (0.50) 2.95 (0.51)
General-Harm (mean, SD)*† 2.94 (0.78) 2.95 (0.50) 2.99 (0.43)
General-Benefit (mean, SD)*† 3.70 (0.53) 3.69 (0.42) 3.55 (0.45)
PSM (mean, SD)*† 2.89 (0.65) 2.35 (0.64) 2.70 (0.68)
MARS score (mean, SD*) 18.8 1 (4.16) 21.51 (3.07) 21.47 (3.86)
*<0.05.
†Excluding missing data.
MARS, medicine adherence report scale; PSM, perceived sensitivity to medicines; RA, rheumatoid arthritis. 
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to 2.05 for the Ambivalent group, 1.27 95% CI 0.60 to 2.68 
for the Sceptical group and 1.27 95% CI 0.69 to 2.34 for 
the Indifferent group. Only patients in the Ambivalent 
group showed a statistical significance.
DIsCussIOn
This is the first large study of this kind that investigates 
beliefs about medicines and medicine non-adherence in 
China in three common chronic diseases. Both unadjusted 
and adjusted results revealed that Specific-Concerns and 
PSM were significantly associated with non-adherence, 
that is, the higher the concern about the medicine or 
the higher perceived sensitivity to medicines. Using the 
continuous MARS-5 scores showed similar relationships 
to those reported in logistic regression (r=−0.09, p<0.01 
for Specific-Concerns and r=−0.09, p<0.01 for PSM). We 
noted differences between groups that might indicate 
different attitudes towards the diseases and their treat-
ments or be attributable to other factors. The hospital 
out-patients (diabetes mellitus and RA) included some 
patients who had previous hospitalisations and come 
back to the hospital for regular monitoring.
Our findings were consistent with the evidence from 
a recent meta-analysis which showed that higher adher-
ence was associated with fewer concerns about treat-
ment10 but not consistent with previous findings that 
higher belief in personal need for treatment was associ-
ated with higher adherence; Specific-Necessity was not 
associated with non-adherence in our overall analysis. 
Subgroup analyses showed that patients with stroke and 
diabetes mellitus showed the same direction association 
as previous studies, that is, patients with higher necessity 
were less likely to be non-adherent. However, an oppo-
site non-statistically significant result of Specific-Necessity 
and adherence for patients with RA (Our result of 1.34 
(95% CI 0.73 to 2.46) for non-adherence equals 0.75, 
95% CI 0.41 to 1.38 for adherence) was observed in the 
study in comparison with the meta-analysis result which 
had a pooled OR of 3.28, 95% CI 1.11 to 9.71 for adher-
ence.10 The point estimate could be due to chance and 
further studies need to confirm the finding. A recent 
study found that General-Benefit may be negatively 
associated with non-adherence among 398 patients with 
epilepsy from the UK primary care population (adjusted 
OR, 0.92, 95% CI 0.63 to 1.34)18 and this association was 
confirmed by our study with a borderline significant OR 
of 0.75 (95% CI 0.56 to 1.02). There was no correlation 
between Necessity and Concern (table 2) in our study 
population and this was supported by a recent Swedish 
study conducted in 578 stroke patients.19 They reported 
a Spearman’s correlation coefficient of 0.075 (p=0.08). 
Compared with patients with high necessity and low 
concerns, patients with high necessity and high concerns, 
low necessity and high concerns, and low necessity and 
low concerns were all associated with non-adherence and 
this was supported by studies conducted in patients with 
inflammatory bowel disease and renal dysfunction.20 21 
High perceived sensitivity to medicines was reported to 
be associated with non-adherence and higher medical 
care utilisation, increased symptom reporting and greater 
information-seeking about medication.18 22 Our study also 
showed that PSM was associated with non-adherence.
Our study has some strengths. First, this was the first 
large BMQ study conducted in China. Second, we choose 
two large teaching hospitals for this study and collected 
data continually until the target numbers were reached 
for each condition. Therefore, our study population was 
more likely to represent the disease population from 
each region as large teaching hospitals provide health-
care service to majority of Chinese patients. However, 
we acknowledge that some patients with transient isch-
aemic attacks (TIAs), a subtype of stroke may not be 
Figure 1 Attitudinal analysis of Beliefs about Medicines Questionnaire (BMQ)-Specific.
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admitted to hospital. Therefore, our stroke inpatients 
may under-represent the TIA patients. Thirdly, China has 
higher prevalence rates of stoke and diabetes mellitus 
than Western Europe and stroke is also the leading cause 
of death in China. In light of the current deteriorated 
relationship between health professional and patients 
(ie, patients do not trust their doctors and other health 
professionals, doctors, nurses are often abused verbally 
and physically by patients),11 23 24 more studies are needed 
from the patients’ perspective. More consideration from 
the patient perspective should be taken into account in 
terms of chronic disease management and the relation-
ship between patients and health professionals. However, 
our study was an observational study. Therefore, the 
results may be confounded by unmeasured factors such as 
comorbidity. Self-reported adherence may not be the best 
measurement for medicine adherence as patients may, 
for example, underestimate how often they forget their 
treatment. However, a strong correlation was found for 
medicine adherence measured by self-reported question-
naire, electronic prescriptions and serum biomarkers in 
a recent intervention study suggesting that self-report is 
a reliable measure.25 Also, our study found relatively low 
Table 3 Correlation matrix between Beliefs about Medicines Questionnaire (BMQ)-Specific, BMQ-General and perceived 
sensitivity to medicines (PSM)
Necessity Concerns Overuse Harm Benefit PSM
Overall
  Necessity 1.00
  Concern 0.02 (0.45) 1.00
  Overuse −0.01 (0.87) 0.39 (<0.01) 1.00
  Harm −0.05 (0.16) 0.49 (<0.01) 0.45 (<0.01) 1.00
  Benefit 0.31(<0.01) −0.09 (0.01) 0.11 (<0.01) 0.04 (0.21) 1.00
  PSM 0.04 (0.22) 0.45 (<0.01) 0.39 (<0.01) 0.38<0.01) 0.05 (0.14) 1.00
Stroke
  Necessity 1.00
  Concern 0.04 (0.43) 1.00
  Overuse 0.06 (0.31) 0.50 (<0.01) 1.00
  Harm −0.06 (0.27) 0.66 (<0.01) 0.57 (<0.01) 1.00
  Benefit 0.36 (<0.01) 0.01 (0.88) 0.24 (<0.01) 0.13 (0.12) 1.00
  PSM 0.23 (<0.01) 0.52 (<0.01) 0.51 (<0.01) 0.50 (<0.01) 0.22 (<0.01) 1.00
Diabetes mellitus
  Necessity 1.00
  Concern 0.02 (0.59) 1.00
  Overuse −0.05 (0.40) 0.26 (<0.01) 1.00
  Harm −0.08 (0.20) 0.21 (<0.01) 0.44 (<0.01) 1.00
  Benefit 0.19 (<0.01) −0.07 (0.26) 0.18 (<0.01) 0.08 (0.19) 1.00
  PSM −0.08 (0.20) 0.36 (<0.01) 0.38 (<0.01) 0.44 (<0.01) 0.07 (0.23) 1.00
RA
  Necessity 1.00
  Concerns 0.01 (0.91) 1.00
  Overuse −0.08 (0.13) 0.41 (<0.01) 1.00
  Harm 0.02 (0.72) 0.42 (<0.01) 0.30 (<0.01) 1.00
  Benefit 0.30 (<0.01) −0.21 (<0.01) −0.20 (<0.01) −0.15 (0.21) 1.00
  PSM −0.04 (0.52) 0.54 (<0.01) 0.29 (<0.01) 0.27 (<0.01) −0.13 (0.02) 1.00
Table 4 ORs of medicine non-adherence
Unadjusted
OR, 95% CI
Adjusted*
OR, 95% CI
Specific-Necessity 0.90, 0.67 to 1.21 0.93, 0.68 to 1.27
Specific-Concerns 1.27, 1.02 to 1.58 1.35, 1.07 to 1.71
General-Overuse 1.32, 1.04 to 1.69 1.15, 0.88 to 1.50
General-Harm 1.09, 0.87 to 1.38 1.12, 0.89 to 1.43
General-Benefit 0.84, 0.63 to 1.12 0.75, 0.56 to 1.02
PSM 1.72, 1.41 to 2.09 1.44, 1.16 to 1.85
*Adjusted for age, gender, education, occupation, duration of the 
disease and different diseases.
PSM, Perceived Sensitivity to Medicines scale.
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reliability of the BMQ general scales and further investi-
gation and refinement might be needed of these Chinese 
translations. The difference in non-adherence between 
stroke and other conditions needs to be explored in 
future studies as disease itself may play an important role 
in medicine adherence.
In conclusion, we found that the BMQ is a useful tool 
to identify psychological factors that are linked to non-ad-
herence in patients with stroke, diabetes and RA. Future 
studies should use the BMQ to screen patients to iden-
tify those who are at high risk of non-adherence and map 
their treatment plan accordingly.
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